Melanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference Call Tuesday, May 13th at 4:30 pm ET
May 07 2014 - 5:23PM
Marketwired
Melanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference
Call Tuesday, May 13th at 4:30 pm ET
IRVINGTON, NY--(Marketwired - May 7, 2014) - MELA Sciences, Inc.
(NASDAQ: MELA), developer of the MelaFind® system, an optical
diagnostic device approved for use in the U.S. and the European
Union to assist dermatologists in melanoma diagnosis, will release
its first quarter 2014 financial results and provide an update on
its activities on Tuesday, May 13, 2014, after the market's close.
MELA Sciences President and CEO, Rose Crane, and the Company's CFO,
Robert Cook, will host a conference call at 4:30pm ET that day to
review the Company's progress and to answer questions.
Conference Call: 845-675-0437 or 866-519-4004 - Passcode:
42498987
Telephone Replay: 855-452-5696 or 646 254 3697 - Available May
13th - May 21st
Live Webcast & Replay:
www.melasciences.com/investors/home
About MELA Sciences, Inc. www.melasciences.com MELA
Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
Company's flagship product is the MelaFind® system, a non-invasive
diagnostic tool to aid dermatologists in melanoma evaluation and
diagnosis, which has secured FDA Pre-Market Approval (PMA) for the
U.S. and CE Marking certification for the European Union. The
MelaFind® system uses a variety of visible to near-infrared light
waves to evaluate skin lesions from the surface to 2.5 mm beneath
the skin. It provides images and data on the relative
disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
Safe Harbor This press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995. These statements include but are not limited to our
plans, objectives, expectations and intentions and may contain
words such as "seeks," "look forward," and "there seems" that
suggest future events or trends. These statements are based on our
current expectations and are inherently subject to significant
uncertainties and changes in circumstances. Actual results may
differ materially from our expectations due to financial, economic,
business, competitive, market, regulatory and political factors or
conditions affecting the company and the medical device industry in
general, as well as more specific risks and uncertainties set forth
in the company's SEC reports on Forms 10-Q and 10-K. Given such
uncertainties, any or all of these forward-looking statements may
prove to be incorrect or unreliable. MELA Sciences assumes no duty
to update its forward-looking statements and urges investors to
carefully review its SEC disclosures available at www.sec.gov and
www.melasciences.com.
Media Diana Garcia Redruello MELA Sciences, Inc. 212-518-4226
Email Contact Investors David Collins, Eric Lentini Catalyst Global
212-924-9800 Email Contact
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Sep 2023 to Sep 2024